BenevolentAI SA is a holding company that engages in the research and development and sale of AI-enabled drugs. Its business platform combines artificial intelligence and machine learning in discovering medicines. Its geographical segments include UK, U.S., and Europe. The company was founded by Ivan Griffin, Kenneth Patrick Mulvany, and Michael Brennan in November 2013 and is headquartered in London, the United Kingdom.